Oraya Therapeutics Inc., - aka Gem Biosystems, Inc. - had been a privately-held company producing a low-energy, stereotactic radiotherapy instrument, IRay, for the treatment of wet AMD. Following the announcement early in 2015 of an investment in Oraya by Carl Zeiss Meditec and the institution of a close working relationship between the two firms, it was announced in April 2016, that the smaller firm had discontinued operations and had been absorbed into Zeiss. Involving management that had previously had professional ties to Carl Zeiss Meditec, Oraya Therapeutics, Inc. had been founded to work on development of innovative and non-invasive therapies for wet age-related macular degeneration. Called Oraya Therapy, the firm's product was a low-voltage, stereotactic, radiosurgical device designed specifically for treatment in an outpatient setting. Oraya Therapy delivers a precise dose of radiation non-invasively to the macula using an automated positioning system, a proprietary localizing algorithm, and a novel methodology for eye stabilization and tracking. The non-invasive Oraya Therapy is rapid, comfortable for the patient, and easy for a trained operator to perform. The low voltage stereotactic radiotherapy device; and gold nanoparticles activated by low-energy radiation therapy to enhance the treatment of wet age-related macular degeneration delivering a precise dose of radiation non-invasively to the macula using an automated positioning system, a localizing algorithm, and a methodology for eye stabilization and tracking. Oraya Therapeutics, Inc. had been previously known as GEM Biosystems, Inc.
